Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Karyopharm Therapeutics (KPTI) Shares Issued (2016 - 2025)

Karyopharm Therapeutics' Shares Issued history spans 13 years, with the latest figure at $405000.0 for Q4 2025.

  • For Q4 2025, Shares Issued fell 40.44% year-over-year to $405000.0; the TTM value through Dec 2025 reached $1.1 million, up 14.94%, while the annual FY2025 figure was $761000.0, 47.59% down from the prior year.
  • Shares Issued reached $405000.0 in Q4 2025 per KPTI's latest filing, down from $680000.0 in the prior quarter.
  • In the past five years, Shares Issued ranged from a high of $2.1 million in Q2 2021 to a low of $11000.0 in Q3 2022.
  • Average Shares Issued over 5 years is $827583.3, with a median of $816500.0 recorded in 2021.
  • Peak YoY movement for Shares Issued: plummeted 98.71% in 2021, then surged 157.58% in 2024.
  • A 5-year view of Shares Issued shows it stood at $896000.0 in 2021, then rose by 29.91% to $1.2 million in 2022, then tumbled by 77.32% to $264000.0 in 2023, then soared by 157.58% to $680000.0 in 2024, then crashed by 40.44% to $405000.0 in 2025.
  • Per Business Quant, the three most recent readings for KPTI's Shares Issued are $405000.0 (Q4 2025), $680000.0 (Q4 2024), and $264000.0 (Q4 2023).